Navigation Links
New target discovered for food allergy treatment
Date:11/1/2012

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1 markedly reduced the allergic response to peanuts.

"Pim 1, and its associated transcription factor, Runx3, play a crucial role in allergic reactions to peanuts," said Dr. Gelfand, senior author and chair of pediatrics at National Jewish Health. "As such, they offer promising new targets for the treatment of allergic reactions to peanuts, and possibly other foods." Pim1 kinase is involved in many signaling pathways and is expressed in T cells and eosinophils, cell types linked to allergic diseases. Runx3 is a transcription factor associated with the regulation of T cells.

In a mouse model of food allergy, the researchers found that Pim1 kinase levels increased in the intestines of allergic mice that had been fed peanuts, as did various inflammatory cells and levels of cytokine molecules associated with allergies. Levels of Runx3 mRNA, however, dropped significantly in the allergic mice. When researchers administered a small molecule that inhibits the activity of Pim 1 kinase, mice no longer experienced diarrhea and other symptoms associated with their peanut allergy.

Plasma levels of histamine, a potent cause of allergy symptoms, dropped to almost baseline levels after administration of AR460770, which is produced by Array Biopharma. Inflammatory mast cells, eosinophils, and CD4 and CD8 T cells all increased only slightly in response to peanuts. Levels of several cytokine signaling molecules associated with allergies, IL-4, IL-6 and IL-13, also dropped after treatment with the Pim 1 inhibitor. Runx3 mRNA, rose back to near baseline levels.

"Our data identified for the first time that Pim1 kinase contributes in important ways to the development of peanut-induced allergic responses, " said Dr. Gelfand. "Targeting this novel regulatory axis involving Pim 1 kinase and Runx3 offers new therapeutic opportunities for the control of food-induced allergic reactions."


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related medicine news :

1. New study finds a common bond between school bullies and their targets: alcohol abuse
2. Biomarkers of behavior, therapeutic targets for adult B-acute lymphoblastic leukemia identified
3. Yeast model offers clues to possible drug targets for Lou Gehrigs disease, study shows
4. Mouse model exposes a new type of T cell to target melanoma
5. Moving targets
6. UGA researchers boost efficacy of drugs by using nanoparticles to target powerhouse of cells
7. Cardiovascular disease community calls for tougher targets to curb global risk
8. Discovery of essential genes for drug-resistant bacteria reveals new, high-value drug targets
9. Large lung cancer study shows potential for more targeted therapies
10. Novel therapeutic targets identified for small cell lung cancer
11. Deadly witch hunts targeted by grassroots womens groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: